摘要
目的:探讨厄贝沙坦片联合盐酸胺碘酮片治疗慢性心力衰竭(CHF)伴心律失常(VA)患者的效果。方法:选取2018年3月—2020年3月在本院确诊的112例CHF伴VA例患者为研究对象,采用简单随机分组将患者分为观察组和对照组,每组56例。对照组采用盐酸胺碘酮片治疗,观察组在对照组基础上加用厄贝沙坦片治疗,比较两组临床疗效、心功能变化指标(QT离散度、心率及射血分数)、血清指标(cTnI、Chemerin水平)及不良反应发生情况。结果:治疗后,观察组治疗总有效率为91.07%,高于对照组的73.21%,差异有统计学意义(P<0.05);观察组QT离散度、心率低于对照组,射血分数高于对照组,差异有统计学意义(P<0.05);观察组血清cTnI、Chemerin水平低于对照组,差异有统计学意义(P<0.05);两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:厄贝沙坦片联合盐酸胺碘酮片治疗CHF伴VA患者疗效确切,可降低血清cTnI、Chemerin水平,改善心功能,且不增加不良反应发生概率。
Objective:To investigate the effect of irbesartan tablets combined with amiodarone hydrochloride tablets in the treatment of chronic heart failure(CHF)with arrhythmia(VA).Methods:A total of 112 patients with CHF and VA diagnosed in our hospital from March 2018 to March 2020 were selected as the research objects.The patients were divided into observation group and control group by simple random grouping,56 cases in each group.The control group was treated with amiodarone hydrochloride tablets,and the observation group was treated with irbesartan tablets on the basis of the control group.The clinical efficacy,cardiac function changes(QT dispersion,heart rate and ejection fraction),serum indexes(cTnI and Chemerin levels)and adverse reactions were compared between the two groups.Results:After treatment,the total effective rate of the observation group was 91.07%,which was higher than 73.21% of the control group,the difference was statistically significant(P<0.05).QT dispersion and heart rate in the observation group were lower than those in the control group,and ejection fraction was higher than that in the control group,the difference was statistically significant(P<0.05).The levels of serum cTnI and Chemerin in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Irbesartan tablets combined with amiodarone hydrochloride tablets is effective in the treatment of CHF patients with VA,which can reduce serum cTnI and Chemerin levels,improve cardiac function,and do not increase the probability of adverse reactions.
作者
王银银
WANG Yinyin(Department of Internal Medicine,First Afiliated Hospital of Henan University of Science and Technology,Luoyang 471003,Henan,China)
出处
《中国药物滥用防治杂志》
CAS
2022年第7期917-920,共4页
Chinese Journal of Drug Abuse Prevention and Treatment
